Early Payer Guidance Across Four Inflammatory Disease Areas

Home / Intelligence / Case Studies / Early Payer Guidance Across Four Inflammatory Disease Areas

Trinity completed an early payer guidance engagement, conducting comprehensive secondary research across four inflammatory disease areas.


Geographic Scope:


Client Situation

The client wanted to gain an in-depth understanding of four inflammatory disease areas to inform early stage decision-making.

Trinity’s Solution

Trinity conducted comprehensive secondary research in the following areas:

  • Disease background including diagnosis, prognosis, epidemiology and unmet needs
  • Current and future paradigm including lines of therapies and standard of care
  • Pipeline analysis including key therapies in development and future treatment gamechangers
  • Pricing and access landscape including pricing analysis, health technology assessment (HTA) outcomes and access status

Deliverables

Four disease-specific early payer guidance reports powered by comprehensive secondary research efforts into disease background, current and future treatment paradigm, pipeline analysis and pricing and access landscape.

Project Outcomes & Impact

Trinity’s comprehensive secondary research and landscape analyses helped the client to make early-stage decisions across therapeutic areas of interest from a future business development perspective.

Related Intelligence

Blog

Rise with the waves: Italy – AIFA restructuring and budget reforms – Stepping into a new (uncertain) future?

Executive Summary The Italian Medicines Agency (AIFA) underwent transformative changes on January 30, 2024, following a much-anticipated reorganization. AIFA’s restructuring has already faced challenges, with the recent resignation of the newly created Scientific and Economic Commission’s (CSE) chairman followed by the appointment of a new acting chairman, highlighting the need for a stable and collaborative […]

 Read More

Webinars

Annual State of Global Market Access Webinar

March 27, 2024 | 12:00 – 12:45 PM ET

Two additional sessions will be offered on March 28:16:00-16:45 (UTC+8:00) – Asia/Shanghai15:00-15:45 CET – Europe/Berlin Trinity Life Sciences is pleased to release our highly anticipated white paper, the Annual State of Global Market Access. This year’s white paper focuses on six key global market access trends and provides payer perspectives on these trends. We explore the […]

 Sign Up Now

White Papers

Annual State of Global Market Access

In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased […]

 Read More